

# Measles is back

Ruth Farrugia, David Pace

## Abstract

Measles is one of the most deadly vaccine preventable diseases. The incidence of measles, and resultant mortality, had dropped drastically following the introduction of widespread measles immunisation since the 1960s. However, there is currently a worldwide surge in measles cases, with a marked increase over the past 3 years. Measles outbreaks and endemic transmission have been re-established in countries which had previously achieved measles elimination. The rise in measles cases has been mainly attributed to a drop in the recommended two dose vaccination schedule below the 95% uptake threshold necessary for interruption of transmission and sustainment of herd protection. This resurgence of measles is largely a result of the damage done by Andrew Wakefield, who in 1998 incorrectly and maliciously suggested a possible link between the measles, mumps and rubella (MMR) vaccine and autism. Such a possible association has subsequently been disproven by several scientifically robust studies. Still, most cases of measles have occurred in unimmunised individuals, mainly teenagers, who had missed out on vaccination in early childhood, and in infants under one year of age, who are too young to be vaccinated. Measles is highly contagious, with up to 18 people being potentially infected from a single case, so containment measures are important to prevent spread. These include isolation and immediate notification of suspected or confirmed cases, as well as wearing appropriate personal protective equipment when in contact with these patients. Health care professionals have a crucial role in promoting measles immunisation, which is the only rational way of preventing measles.

Measles is one of the most deadly vaccine-preventable diseases<sup>1</sup> and is included in the top overall causes of death in children under 5 years of age worldwide.<sup>2</sup>

Prior to the introduction of widespread measles vaccination in 1963, measles accounted for about 2.6 million deaths annually.<sup>3</sup> In fact, one of the aims of the Global Vaccine Action Plan 2011 – 2020<sup>4</sup> was the elimination of measles in 4 out of 5 World Health Organization (WHO) regions by 2015, but this aim has not been achieved.<sup>5</sup> Measles elimination is defined as the absence of endemic measles virus transmission in a region or other defined geographic area for  $\geq 12$  months, in the presence of a high quality surveillance system that meets targets of key performance indicators.<sup>6</sup>

In theory, eradication of measles is possible because humans are the only reservoirs,<sup>7</sup> measles is only infectious during the acute phase,<sup>7</sup> specific and rapid diagnostic tests are available,<sup>8</sup> the measles virus is monotypic<sup>8</sup> and a monovalent vaccine is effective against all known virus isolates.<sup>8</sup>

The measles virus is aerosol-borne and is easily spread by coughing and sneezing, close personal contact or direct contact with infected nasal or throat secretions.<sup>3</sup> Measles is highly contagious, starting from four days prior onset of the rash until four days following rash appearance.<sup>1</sup> Over 90% of contacts develop the disease.<sup>9</sup> The basic reproduction number ( $R_0$ ) for measles lies between 12 and 18,<sup>10</sup> meaning that a single patient with measles may infect up to 18 susceptible people.<sup>9</sup> In comparison,  $R_0$  for influenza is estimated between 2 and 4<sup>11</sup> while  $R_0$  for varicella ranges between 3.7 and 5.<sup>12</sup>

The clinical description for measles by the Centers for Disease Control and Prevention (CDC) states that measles is an acute illness characterised by a generalised maculopapular rash that is present for at least 3 days, an oral temperature of at least 101 °F (38.3 °C) and the presence of cough, coryza, and conjunctivitis.<sup>13</sup> The pathognomonic Koplik spots on the buccal mucosa, which are not always present, are not a diagnostic criterion.<sup>7</sup> The incubation period for measles is 10 days for onset

**Ruth Farrugia\***, MD, MRCPCH (UK), MSc PEM (Edin)  
ruth.b.farrugia@gov.mt

**David Pace**, MD, Pg Dip PID (Oxf), FRCPCH, PhD

*\*Corresponding author*

of fever; the rash usually appears 4 days later.<sup>7</sup> Laboratory diagnosis, which is a requisite for case confirmation, may be performed by detecting measles IgM in serum or saliva.<sup>14</sup> Of note, 30% may be negative in the initial 3 days and the tests should not be performed later than 4 weeks from onset of the rash.<sup>15</sup> False positives may occur especially with rubella and parvovirus B19 infections.<sup>16</sup> PCR testing on respiratory secretions, nasopharyngeal swab, blood or urine may be needed for genetic characterisation of the virus, which can help identify the source of infection.<sup>17</sup> There is no specific treatment for measles.

Measles complications can occur in up to 40% of patients and are more common in high-risk patients.<sup>7</sup> Pneumonia occurs in up to 1 in 16 patients<sup>18</sup> and is the leading cause of measles-associated death.<sup>1</sup> Other complications include otitis media (in about 1 in 12 measles cases)<sup>18</sup>, diarrhoea (in about 1 in 12 measles cases),<sup>18</sup> ocular complications and central nervous system manifestations, such as encephalitis (in about 1 in every 1000 - 2000 measles cases)<sup>18</sup> or subacute sclerosing panencephalitis (in about 4 - 11 per 100,000 measles cases).<sup>1</sup> Measles also causes long-lasting memory B and T cell impairment.<sup>19</sup> High-risk patients include immunosuppressed patients (in whom typical signs and symptoms may be absent), patients with Vitamin A deficiency, malnourished patients and travellers.<sup>7</sup> Young infants also have a higher risk of mortality and complications,<sup>7</sup> especially if born to mothers with vaccine-derived immunity or who are infected with HIV.<sup>20</sup> Passive immunity lasts longer in mothers with natural immunity to measles but by 6 months of age less than 5% of all infants retain maternal antibodies.<sup>21</sup>

A proportion of individuals with measles will need hospital admission. Unfortunately, hospital admission is associated with measles transmission,<sup>22</sup> including outbreaks amongst healthcare workers.<sup>23</sup> The cost of delay in diagnosis and the resultant potential exposure is prohibitive, in view of the high infectivity of measles.<sup>24</sup> Patients suspected of having measles should be isolated immediately and measures should be in place to prevent further spread during outbreaks. The virus remains infective for two hours on solid surfaces, which should be borne in mind when decontaminating a room.<sup>25</sup> Infection control measures should be implemented as per local recommendations and respiratory protection by

means of N95 or FFP3 (filtering facepiece class 3) mask should be worn when attending to a patient with suspected or confirmed measles,<sup>26</sup> irrespective of the immunity of the healthcare worker to measles. A normal surgical mask should be worn if a FFP is not available – this will still provide a reasonable level of protection.<sup>27</sup>

The only rational way of preventing measles in a population is through vaccination. The MMR (measles, mumps, rubella) vaccine has 99% effectiveness against measles following 2 doses,<sup>28</sup> is well tolerated, safe,<sup>29</sup> and offers long-lasting protection.<sup>30</sup> In fact, measles vaccination is estimated to have prevented 20.4 million deaths between 2000 – 2016.<sup>31</sup> However, in view of the high  $R_0$  for measles, a high uptake of at least 95% for both doses is needed in order to eliminate measles from a population and to attain herd protection.<sup>32-33</sup>

In Malta, the first dose of MMR vaccine is administered at 13 months of age, with the second dose being given at 3 to 4 years of age.<sup>34</sup> This is in line with the WHO recommendations that two doses of measles-containing vaccine, such as the MMR vaccine, for countries with low risk of measles should be given at around 12 months of age for the first dose and that the second dose of MMR vaccine should be given at the age when maximum coverage at national level is anticipated.<sup>35</sup> A supplementary dose of measles vaccine is recommended from 6 months of age onwards during measles outbreaks<sup>35</sup>. Any dose of measles vaccine given before 12 months of age should not be counted as part of the series and these children should be revaccinated with 2 doses of the MMR vaccine after 12 months of age.<sup>36</sup>

Unfortunately, measles immunisation rates have dropped globally. During 2017, 85% of children received one dose of measles vaccine by their second birthday, with only 67% receiving the second dose as part of routine immunisation.<sup>37</sup> In Europe, immunisation rates for 2017 were 95% for the first dose and 90% for the second dose.<sup>38</sup> The single most influential factor for the drop in measles vaccine uptake was an article by Dr Andrew Wakefield in *The Lancet* in 1998,<sup>39</sup> which suggested a potential link between the MMR vaccine and developmental regression and autism, among other conditions. This paper received disproportionate media coverage and caused the biggest public health scare in UK history.<sup>40</sup> Flaws

in research methods were immediately pointed out, including that it was a case series of 12 children without controls and that data collection relied on parent's personal beliefs and recalls.<sup>41</sup> Large epidemiological studies over the years,<sup>42-46</sup> as well as a WHO extensive review<sup>47</sup> and a Cochrane systematic review,<sup>48</sup> have since disproved any links between the MMR vaccine and autism. The UK General Medical Council found that Dr Wakefield had falsified his data and had breached ethical standards in this publication<sup>49</sup> and consequently he was struck off the register because of his serious professional misconduct.<sup>50</sup> The paper was also withdrawn by *The Lancet* in 2010.<sup>51</sup> However, it is still widely quoted by anti-vaccine campaigners and parents, some of whom remain unsure whom to believe, despite all the robust scientific evidence proving that the MMR vaccine is not associated with autism.<sup>52</sup>

Endemic transmission of measles can be re-established once vaccination rates fall below the elimination threshold.<sup>53</sup> In fact, measles has again become endemic in all five WHO regions during 2018, with the rate of measles being the highest in a decade<sup>54</sup> and continuing to rise by a further 300% during the first quarter of 2019.<sup>55</sup> Over 82,000 people in the WHO European region contracted measles during 2018, with up to 61% needing hospitalisation and 72 deaths in children and adults.<sup>38</sup> This is more than three times as many as in 2017, 15 times as many as in 2016<sup>18</sup> and even surpassed the number of measles cases in the WHO African region in 2018, which totalled 33,879.<sup>56</sup> This figure includes national outbreaks in countries having previously achieved measles elimination, such as The Netherlands<sup>57</sup> and Greece,<sup>58</sup> and also the re-establishment of endemic transmission in countries where measles had been eliminated, as happened in the United Kingdom.<sup>59</sup>

Malta has maintained the status of measles elimination in 2018, because there have not been any cases of measles due to sustained transmission.<sup>60</sup> However, there is an increasing trend in locally acquired measles, rising from 6 cases in 2018<sup>60</sup> to 15 confirmed cases so by April 2019 - 23 cases in adults and 2 cases in children.<sup>61</sup> During 2018, 95.5% of children in Malta received the first dose of MMR and 95% received the second dose of MMR vaccine.<sup>62</sup> This is in contrast to previous years, when immunisation rates in Malta had dropped below the 95% uptake rate (for both

doses) needed to prevent disease transmission. In fact, only 91% of children received the first dose of MMR vaccine and 83% received the second dose during 2017<sup>63</sup>, although this could be a result of inadequate notification. This is the ideal scenario for breakthrough cases of measles and, in the absence of herd protection, the potential for outbreaks, as has happened in other countries.

Indeed, the surge in measles in Europe has been mainly attributed to a drop in two-dose measles vaccine coverage below 95% and a drop in prevalence of individuals with vaccine-induced protection of measles to less than 94.4%.<sup>64</sup> Out of the 14,400 reported cases of measles in Europe in 2017<sup>65</sup> with known vaccination status, 87% were unimmunised, 8% had received one dose of measles-containing vaccine, 3% had received two or more doses of vaccine and 2% were vaccinated with an unknown number of doses.<sup>66</sup> Immunisation status was unknown for 6%.<sup>66</sup> Thirty seven percent of measles occurred in children under 5 years of age, with the highest disease burden occurring in children below the age of 1 year, while 45% occurred in patients older than fifteen years.<sup>66</sup> Therefore, nearly half of the measles cases in Europe occurred in unimmunised adolescents aged 15 years or older, highlighting the need to identify and catch-up those who missed out on routine vaccination in childhood.

The resurgence of measles at a global level is being driven by multiple factors, including conflict, poor health education, lack of access to health care, complacency, increasing vaccine hesitancy and low support amongst medical personnel.<sup>67</sup> In addition, vaccine coverage may be suboptimal in at-risk groups, including Roma, Irish travellers, orthodox religious communities<sup>67</sup> and adolescent and adult migrants, who might be excluded from the immunisation catch-up initiatives provided to younger children.<sup>68</sup> Failure to address vaccination shortfalls in vulnerable populations will create immunisation gaps and lead to subnational coverage.

Measles is a vaccine-preventable disease which carries a high morbidity and mortality. Elimination of measles is dependent on sustaining herd protection and in limiting transmission during outbreaks. Our role as health care professionals is to actively encourage MMR vaccine uptake, including opportunistic vaccination for those who were not immunised at the appropriate times, address public

concerns, expedite the diagnosis of measles, notify immediately any suspected or confirmed cases and help in containing outbreaks.

## References

- Buchanan R, Bonthius D. Measles virus and associated central nervous system sequelae. *Seminars in paediatric neurology*. 2012;19(3):107-4.
- World Health Organization. Global Health Observatory data: Causes of Child Mortality, 2017. [Internet]. 2018 [cited 8<sup>th</sup> April 2019]. Available from: [https://www.who.int/gho/child\\_health/mortality/causes/en/](https://www.who.int/gho/child_health/mortality/causes/en/)
- World Health Organization. Measles Fact Sheet. [Internet]. 2018 [cited 28<sup>th</sup> March 2019]; Nov 29. Available from: <https://www.who.int/news-room/fact-sheets/detail/measles>
- World Health Organization. Global Vaccine Action Plan 2011 – 2020. [Internet]. 2013 [cited 8<sup>th</sup> April 2019]. Available from: [https://www.who.int/immunization/global\\_vaccine\\_action\\_plan/GVAP\\_doc\\_2011\\_2020/en/](https://www.who.int/immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/)
- World Health Organization Resolution. Renewed commitment to elimination of measles and rubella and prevention of congenital rubella syndrome by 2015 and sustained support for polio-free status in the WHO European region. WHO Regional Office for Europe, Moscow, Russia. [Internet]. 2010 [cited 8<sup>th</sup> April 2019]. Available from: [http://www.euro.who.int/\\_\\_data/assets/pdf\\_file/0016/122236/RC60\\_eRes12.pdf](http://www.euro.who.int/__data/assets/pdf_file/0016/122236/RC60_eRes12.pdf)
- World Health Organization. Monitoring progress towards measles elimination. *Weekly epidemiological record*. 2010;85:489-96.
- Moss WJ, Griffin DE. Measles. *Lancet*. 2012;379:153-164.
- Meissner HC, Sterbel PM, Orenstien WA. Measles vaccines and the potential for worldwide eradication of measles. *Pediatrics*. 2004;114:1065-1069.
- Holzmann H, Hengel H et al. Eradication of measles: remaining challenges. *Medical Microbiology and Immunology*. 2016;March 2:1-8.
- Guerra FM, Bolotin S et al. The basic reproduction number (R<sub>0</sub>) of measles: a systematic review. *Lancet Infectious Diseases*. 2017;17(12), e420–e428.
- Scarborough Lefebvre CD, Terlinden A, Standaert B. Dissecting the indirect effects caused by vaccines into the basic elements. *Human Vaccines and Immunotherapeutics*. 2015;11(9):2142-2157.
- Marangi L, Mirinaviciute G et al. The natural history of varicella zoster virus infection in Norway: Further insights on exogenous boosting and progressive immunity to herpes zoster. *PLoS ONE* 2017;12(5):e0176845.
- Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System (NNDA): Measles/Rubeola 2013 Case Definition [Internet]. 2013 [cited 8<sup>th</sup> April 2019]. Available from: <https://wwwn.cdc.gov/nndss/conditions/measles/case-definition/2013/>
- Bellini WJ, Hefland RF. The challenges and strategies for laboratory diagnosis of measles in an international setting. *Journal of Infectious Diseases*. 2003;187(Suppl 1):S283-90.
- Hefland RF, Kebede S et al. The effect of timing of sample collection on the detection of measles-specific IgM in serum and oral fluid samples after primary measles vaccination. *Epidemiology and Infection*. 1999;12(3):451-5.
- Brown DWG, Ramsay MB et al. Salivary diagnosis of measles: A study of notified cases in the United Kingdom, 1991-1993. *British Medical Journal*. 1994;308(6395):1015-7.
- Rota PA, Liffick SL et al. Molecular epidemiology of measles viruses in the United States, 1997-2001. *Emerging Infectious Diseases*. [Internet]. 2002 [cited 8<sup>th</sup> May 2016];8(9):902-908. Available online: [http://wwwnc.cdc.gov/eid/article/8/9/02-0206\\_article](http://wwwnc.cdc.gov/eid/article/8/9/02-0206_article)
- Oxford Vaccine Group. Vaccine Knowledge Project: Measles. [Internet]. 2019 [cited 1st April 2019]; Mar 7. Available from: <http://vk.ovg.ox.ac.uk/measles>
- Mina MJ, Metcalf CJE et al. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. *Science*. 2015;348(6235):694-9.
- Perry RT, Mmiro F et al. Measles infection in HIV-infected African infants. *Annals of the New York Academy of Sciences*. 2000;918:377-380.
- Leuridan E, Hens N et al. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. *British Medical Journal*. 2010;340:c1626.
- Hungerford D, Cleary P et al. Risk factors for transmission of measles during an outbreak: matched case-control study. *Journal of Hospital Infection*. 2014;86:138-43.
- Duarte S. Practice what you preach: measles vaccination coverage and outbreaks in healthcare workers in Europe. *European Journal of Public Health*. 2018(28:4):381-382.
- Helmecke MR, Elmendorf SL et al. Measles investigation: a moving target. *American Journal of Infection Control*. 2014;42:911-5.
- Ritcher S, Hawkins A, Painter L. Measles on the rise: academic institutions be prepared. *Perspectives in Learning: A Journal of the College of Education & Health Professions*. [Internet]. 2012 [cited 1st April 2019];13(1):33-38. Available online: [https://perspectives.columbusstate.edu/v13\\_i\\_1/MeaslesOnTheRise.pdf](https://perspectives.columbusstate.edu/v13_i_1/MeaslesOnTheRise.pdf)
- European Centre for Disease Prevention and Control. Safe use of personal protective equipment in the treatment of infectious diseases of high consequence – version 2 [Internet]. 2014 [cited 8<sup>th</sup> April 2019]; Dec 2. Available from: <https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/safe-use-of-ppe.pdf>

27. Office of the Superintendent of Public Health. Letter to doctors [Internet]. 2018 [cited 8<sup>th</sup> April 2019]; Aug 1. Available from: [https://deputyprimeminister.gov.mt/en/administration-and-communication/Documents/Circulars/Measles\\_Doctors\\_03.08.01.pdf](https://deputyprimeminister.gov.mt/en/administration-and-communication/Documents/Circulars/Measles_Doctors_03.08.01.pdf)
28. Pillsbury A, Quinn H. An assessment of measles vaccine effectiveness, Australia, 2006-2012. *Western Pacific Surveillance and Response*. 2015;6(3):43-50.
29. Klein NP, Lewis E et al. Safety of measles-containing vaccines in 1-year-old children. *Pediatrics*. 2015;135(2):2321-329.
30. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. *The New England Journal of Medicine*. 2007;357:1903-1915.
31. Dabbagh A, Patel MK et al. Progress towards regional measles elimination - worldwide 2010 – 2016. *Morbidity and Mortality Weekly Report*; US Department of Health and Human Services/Centers for Disease Control and Prevention. 2017;66(42):1148-1153.
32. van Boven M, Kretzschmar M et al. Estimation of measles vaccine efficacy and critical vaccination coverage in a highly vaccinated population. *Journal of the Royal Society Interface*. 2010;7(52):1537-1544.
33. Glick M. Vaccine hesitancy and unfalsifiability. *Journal of the American Dental Association*. 2015;146(7):491-493.
34. Primary Health Care. National Immunisation Schedule 2017 [Internet]. 2017 [cited 8<sup>th</sup> April 2019]. Available from: <https://deputyprimeminister.gov.mt/en/phc/pchyhi/Pages/National-Immunisation-Schedule.aspx>
35. World Health Organization. Summary of the WHO position on measles vaccine – April 2017 [Internet]. 2017 [cited 8<sup>th</sup> April 2019]. Available from: [https://www.who.int/immunization/policy/position\\_papers/WHO\\_PP\\_measles\\_vaccine\\_summary\\_2017.pdf?ua=1](https://www.who.int/immunization/policy/position_papers/WHO_PP_measles_vaccine_summary_2017.pdf?ua=1)
36. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases: measles [Internet]. Updated 2015 [cited 8<sup>th</sup> April 2019]; July 24. Available from: <https://www.cdc.gov/vaccines/pubs/pinkbook/meas.html>
37. World Health Organization. Immunization Coverage [Internet]. 2018 [cited 8<sup>th</sup> April 2019]; July 16. Available from: <https://www.who.int/en/news-room/fact-sheets/detail/immunization-coverage>
38. World Health Organization. Measles in Europe: record number of both sick and immunized. [Internet]. 2019 [cited 28<sup>th</sup> March 2019]; Feb 7. Available from: <http://www.euro.who.int/en/media-centre/sections/press-releases/2019/measles-in-europe-record-number-of-both-sick-and-immunized>
39. Wakefield AJ, Murch SH et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. *The Lancet*. 1998;351:637-41.
40. Kmietowicz Z. Wakefield is struck off for the ‘serious and wide-ranging findings against him’. *British Medical Journal*. 2010;340:c2803.
41. Payne C, Mason B. Autism, inflammatory bowel disease, and MMR vaccine. *Lancet*. 1998;351:907.
42. Black C, Kaye JA, Jick H. Relation of childhood gastrointestinal disorders to autism: nested case-control study using data from the UK General Practice Research Database. *British Medical Journal*. 2002;325:419-21.
43. Madsen KM, Hviid A et al. A population-based study of measles, mumps and rubella vaccination and autism. *New England Journal of Medicine*. 2002;347(19):1477-1482.
44. Taylor B, Miller E et al. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. *British Medical Journal*. 2002;324(7334):393–396.
45. Honda H, Shimizu Y, Rutter M. No effect of MMR withdrawal on the incidence of autism: a total population study. *Journal of Child Psychology and Psychiatry*. 2005;46(6):572-579.
46. Hornig M, Briese T et al. Lack of Association between Measles Virus Vaccine and Autism with Enteropathy: A Case-Control Study. *PLoS ONE* 3(9): e3140.
47. World Health Organization. MMR and Autism. *Weekly epidemiological record*. 2003;78:18.
48. Demicheli V, Rivetti A et al. Vaccines for measles, mumps and rubella in children. *Cochrane Database of Systematic Reviews*. 2012, Issue 2, Art. No: CD004407.
49. "General Medical Council, Fitness to Practise Panel Hearing, 28 January 2010, Andrew Wakefield, John Walker Smith, Simon Murch". [Internet]. General Medical Council. 2010 [cited 8<sup>th</sup> April 2019], January 28. Available from: <https://briandeer.com/solved/gmc-charge-sheet.pdf>
50. "General Medical Council, Fitness to Practise Panel Hearing, 24 May 2010, Andrew Wakefield, Determination of Serious Professional Misconduct". [Internet]. General Medical Council. 2010 [cited 8<sup>th</sup> April 2019], May 24. Available from: [https://web.archive.org/web/20110809092833/http://www.gmc-uk.org/Wakefield\\_SPM\\_and\\_SANCTION.pdf\\_32595267.pdf](https://web.archive.org/web/20110809092833/http://www.gmc-uk.org/Wakefield_SPM_and_SANCTION.pdf_32595267.pdf)
51. The editors of the *Lancet*. Retraction - Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. *Lancet*. 2010;375:445.
52. Hilton S, Petticrew M, Hunt K. Parents’ champions vs. vested interests: Who do parents believe about MMR? A qualitative study. *BMC Public Health*. 2007;7:42.
53. Bester JC. Measles and measles vaccination – a review. *JAMA Pediatrics*. 2016(Oct 3):E1-E7.
54. World Health Organization. 2018 Assessment report of the global vaccine action plan. [Internet]. 2018 [cited 1<sup>st</sup> April 2019]. Available from: [https://www.who.int/immunization/global\\_vaccine\\_action\\_plan/SAGE\\_GVAP\\_Assessment\\_Report\\_2018\\_EN.pdf?ua=1](https://www.who.int/immunization/global_vaccine_action_plan/SAGE_GVAP_Assessment_Report_2018_EN.pdf?ua=1)
55. World Health Organization. New measles surveillance data for 2019. [Internet]. 2019 [cited 15<sup>th</sup> April 2019]; Apr 15. Available from: <https://www.who.int/immunization/newsroom/measles-data-2019/en/>

56. United Nations. Measles cases nearly doubled in a year, UN health agency projects. [Internet]. 2019 [cited 28<sup>th</sup> March 2019]; Feb 14. Available from: <https://news.un.org/en/story/2019/02/1032771>
57. Knol M, Urbanus A et al. Large ongoing measles outbreak in a religious community in the Netherlands since May 2013. *Euro Surveillance*. 2013;18(36):20580.
58. Georgakopoulou T, Horefti E et al. Ongoing measles outbreak in Greece related to the recent European-wide epidemic. *Epidemiology and Infection*.2018;147(13):1692-8.
59. Measles once again endemic in the United Kingdom. *Euro Surveillance*. 2008;13(27):18919.
60. Superintence of Public Health. Press release PR190563 [Internet]. 2019 [cited 28<sup>th</sup> march 2019]; Mar 19. Available from: <https://www.gov.mt/en/Government/DOI/Press%20Releases/Pages/2019/March/19/pr190563.aspx>
61. Office of the Superintendent of Public Health, Malta. Information sheet measles [email]. 2019; April 26.
62. Data obtained from National Immunisation Programme, Floriana. Personal communication with Dr Victoria Farrugia Sant'Angelo. 2019; April 29.
63. World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2018 global summary. [Internet]. 2018 [cited 8<sup>th</sup> April 2019];Oct 22. Available from: [https://apps.who.int/immunization\\_monitoring/globalsummary/countries?countrycriteria%5Bcountry%5D%5B%5D=MLT#](https://apps.who.int/immunization_monitoring/globalsummary/countries?countrycriteria%5Bcountry%5D%5B%5D=MLT#)
64. Plans-Rubio P. Why does measles persist in Europe? *European Journal of Clinical Microbiology and Infectious Diseases*. 2017;Oct;36(10):1899-1906.
65. European Centre for Disease Prevention and Control. Measles and rubella surveillance – 2017. [Internet]. 2018 [cited 28<sup>th</sup> March 2019]; Apr 23. Available from: <https://ecdc.europa.eu/en/publications-data/annual-measles-and-rubella-monitoring-report-2017>
66. European Centre for Disease Prevention and Control. Risk of measles transmission in the EU/EAA. [Internet]. 2018 [cited 28<sup>th</sup> March 2019]; March 23. Available from: [https://ecdc.europa.eu/sites/portal/files/documents/Measles-rapid-risk-assessment-European-Union-countries\\_0.pdf](https://ecdc.europa.eu/sites/portal/files/documents/Measles-rapid-risk-assessment-European-Union-countries_0.pdf)
67. Williams GA, Bacci S et al. Measles among migrants in the European Union and the European Economic Area. *Scandinavian Journal of Public Health*. 2016;44:6-13.
68. Hargreaves S, Nellums LB et al. Who is responsible for the vaccination of migrants in Europe? *Lancet*. 2018;391(10132):1752-4.